These data revealed that IL-2 treatment significantly enhanced CD25 and OX40 expression on CD8 T cells localized in the tumor (Fig. 5A), while no significant differences were detected on CD8 T cells in the spleen (Fig. 5B). The gene discussed is TNFRSF4; the disease is neoplasm.